



Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

Jason A Roberts, Mohd H Abdul-Aziz, Jeffrey Lipman, Johan W Mouton, Alexander A Vinks, Timothy W Felton, William W Hope, Andras Farkas, Michael N Neely, Jerome J Schentag, George Drusano, Otto R Frey, Ursula Theuretzbacher, Joseph L Kuti, on behalf of The International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases

Lancet Infect Dis 2014;
14: 498–509

Published Online

April 24, 2014

[http://dx.doi.org/10.1016/S1473-3099\(14\)70036-2](http://dx.doi.org/10.1016/S1473-3099(14)70036-2)

Burns, Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, QLD, Australia (Prof J A Roberts PhD, M H Abdul-Aziz BPharm, Prof J Lipman MD); Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia

(Prof J A Roberts, Prof J Lipman); Nijmegen Medical Centre, Radboud University, Nijmegen, Netherlands (Prof J W Mouton PhD);

Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA (Prof A A Vinks PhD);

Faculty of Science, University of Manchester, Manchester, UK (Dr T W Felton MBBS);

Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK

(Prof W W Hope PhD); Department of Pharmacy, Nyack Hospital, Nyack, NY, USA (Dr A Farkas PharmD);

Laboratory of Applied Pharmacokinetics, University of Southern California, Los Angeles, CA, USA

(M Neely MD); School of Pharmacy, University of Buffalo, Buffalo, NY, USA

(Dr J J Schentag PharmD); Institute for Therapeutic Innovation, College of

Medicine, Department of Medicine, University of Florida, Gainesville, FL, USA

(Prof G Drusano MD); Department of Pharmacy, Heidenheim Hospital, Heidenheim, Germany

(Dr O R Frey PhD); Center for Anti-Infective Agents, Vienna, Austria

Infections in critically ill patients are associated with persistently poor clinical outcomes. These patients have severely altered and variable antibiotic pharmacokinetics and are infected by less susceptible pathogens. Antibiotic dosing that does not account for these features is likely to result in suboptimum outcomes. In this Review, we explore the challenges related to patients and pathogens that contribute to inadequate antibiotic dosing and discuss how to implement a process for individualised antibiotic therapy that increases the accuracy of dosing and optimises care for critically ill patients. To improve antibiotic dosing, any physiological changes in patients that could alter antibiotic concentrations should first be established; such changes include altered fluid status, changes in serum albumin concentrations and renal and hepatic function, and microvascular failure. Second, antibiotic susceptibility of pathogens should be confirmed with microbiological techniques. Data for bacterial susceptibility could then be combined with measured data for antibiotic concentrations (when available) in clinical dosing software, which uses pharmacokinetic/pharmacodynamic derived models from critically ill patients to predict accurately the dosing needs for individual patients. Individualisation of dosing could optimise antibiotic exposure and maximise effectiveness.

Introduction

Patients in intensive care units differ considerably from those in general ward environments and have substantially higher mortality rates. These patients are usually critically ill and have a high level of sickness severity that is associated with profound pathophysiological changes requiring aggressive medical interventions.^{1,2} Health-care providers are treating a growing number of critically ill patients, but clinical outcomes for many subgroups of patients are not improving substantially.³ In particular, critically ill patients with sepsis, septic shock, or acute kidney injury, are a substantial challenge to infectious diseases physicians, critical care physicians, nephrologists, and clinical pharmacists and pharmacologists.

In studies of sepsis and septic shock, interventions that optimised antibiotic therapy improved clinical outcomes the most.^{4–9} Early and appropriate antibiotic administration reduces mortality rates,^{6–8} but less information is available about the effect of appropriate dose regimens on clinical outcome.¹⁰ Although robust data are available for exposure effect relations between antibiotics and bacterial killing in vitro and in animals,^{11,12} the effect of antibiotic exposure on mortality has not been defined as precisely, although, some studies of these relations, mostly observational or retrospective in nature, are available.

Results from a randomised controlled trial with aminoglycosides by van Lent-Evers and colleagues¹³ showed that a dedicated therapeutic drug-monitoring intervention (also described as therapeutic drug management) in a general patient cohort in one hospital significantly reduced their length of stay (mean 20·3 days [SD 1·4]), compared with the length of stay for patients who did not have therapeutic drug monitoring (26·3 [2·9]; $p=0·045$).¹³ Studies of quinolones,^{10,14,15} β lactams,^{10,16–19} glycopeptides,^{20,21}

and linezolid²² all have results from at least retrospective cohort analyses that show advantages in terms of clinical cure, mortality, or both, associated with achievement of target pharmacokinetic/pharmacodynamic indices. The major challenge for clinicians is to ensure that dosing achieves these pharmacokinetic/pharmacodynamic targets in all patients.

Information about effective antibiotic dosing specifically for critically ill patients is not usually included in treatment guidelines—product information for the antibiotic usually guides the choice of dose for such patients. However, product information is based on dose-finding studies in patients who are not critically ill, and the results are then extrapolated to critically ill patients, which might not be accurate for this population. Many critically ill patients have severely altered pharmacokinetic characteristics, which might reduce the likelihood that they will achieve the pharmacokinetic/pharmacodynamic targets that are associated with improved likelihood of positive clinical outcomes.^{23,24} Even general dosing guidelines for patients in intensive care units might not be a satisfactory solution because critically ill patients have substantial pharmacokinetic variability. Increased pharmacokinetic variability reduces the ability to predict therapeutic doses of antibiotic for individual patients, which could potentially worsen outcomes for patients.

After many years of dosing antibiotics in critically ill patients with a “one dose fits all” strategy there is a strong rationale to move to an individualised approach to dosing. This change is further supported by the problem of reduced antibiotic development, the need to make better use of currently available antibiotics, and the growing problem of antibiotic resistance.

In this Review, we describe the challenges of changes in pharmacokinetic characteristics caused by

pathophysiological changes often seen in critically ill patients, and the challenges of the reduced susceptibility to antibiotics of bacterial organisms that is frequently encountered in intensive care. Either pharmacokinetics or pharmacodynamics, or both, affect the pharmacokinetic/pharmacodynamic ratio, and in turn, the magnitude of the pharmacokinetic/pharmacodynamic target. Therefore, we considered solutions to these challenges in the form of individualised dosing strategies, supported by different bedside dosing techniques based on software packages.

Challenge 1: effect of critical illness on antibiotic pharmacokinetics

Overview

Dysfunction of one or many organ systems occurs in critical illness and might substantially change antibiotic concentrations from those seen in patients who are not critically ill (figure). Without rational dose adjustment, these changes in drug concentrations can predispose patients to clinical failure, emergence of antimicrobial resistance, or even toxic effects from the drug. Therefore we first review the pharmacokinetic effects caused by dysfunction of the cardiovascular, renal, pulmonary, and hepatic systems.

Cardiovascular system

Critically ill patients frequently have systemic inflammatory response syndrome caused by pathological changes that are either infectious or non-infectious.²⁵ A major consequence of systemic inflammatory response syndrome, particularly in patients with severe sepsis and septic shock, is extreme fluid extravasation into interstitial space from endothelial damage and capillary leakage. This extravasation, known as third spacing,²⁵ results in hypotension; in response clinicians give large volumes of resuscitation fluids that might also distribute into interstitial fluid and thereby substantially increase interstitial volume. For hydrophilic antibiotics, a rise in interstitial volume might lead to a large increase in

volume of distribution.²⁶ By contrast, lipophilic antibiotics (eg, fluoroquinolones and macrolides) have an inherently larger volume of distribution that is often not greatly affected by such fluid movements or administration.²⁷

Volume of distribution for hydrophilic antibiotics such as aminoglycosides,^{28,29} β lactams,^{26,30} glycopeptides,³¹ and linezolid³² can be up to two times greater in critically ill patients, than in patients who are not critically ill.

Hypoalbuminaemia, defined as a serum albumin concentration less than 25 g/L, is a common but frequently neglected disorder in intensive care units (incidence 40–50%).³³ Uldemolins and colleagues³⁴ have reviewed hypoalbuminaemia in detail and concluded that its effect on antibiotic pharmacokinetic characteristics in critically ill patients might be clinically important. Reduced concentrations of albumin could raise the unbound fraction of protein-bound drugs such as antibiotics.³⁵ Unbound fractions of antibiotics are available not only for elimination, but also for distribution. For antibiotics that are moderately to highly-protein bound (eg, ceftriaxone,³⁶ flucloxacillin,³⁷ ertapenem,^{38,39} and daptomycin⁴⁰) the volume of distribution rises by up to 100% in critically ill patients with hypoalbuminaemia. Fluid shifts and altered protein-binding, both often seen in mechanically ventilated patients, raise volume of distribution. An increased volume of distribution might reduce the peak concentration of drugs, which might in turn reduce the effectiveness of antibiotics that are concentration-dependent (eg, aminoglycosides). These drugs need a high ratio of maximum concentration of unbound antibiotic to minimum inhibitory concentration and a high ratio of area under the concentration–time curve to minimum inhibitory concentration for maximum bacterial killing.^{41–43} However, for a drug that is highly protein-bound (eg, daptomycin), hypoalbuminaemia will probably lead to a high free fraction of antibiotic in the early part of the dosing interval, which might result in advantageously high unbound concentrations. By contrast, for time-dependent β lactam antibiotics, changes in volume of distribution and protein binding can lead to

(Dr U Theuretzbacher PhD); and Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA (Dr J L Kuti PharmD)

Correspondence to: Prof Jason A Roberts, Burns, Trauma and Critical Care Research Centre, The University of Queensland, Royal Brisbane and Women's Hospital, Herston, QLD 4029, Australia
j.roberts2@uq.edu.au




Figure: The range of altered pathophysiology in patients with critical illness, and its effects on drug concentrations
RRT=renal replacement therapy. ECMO=extracorporeal membrane oxygenation.

low unbound concentrations later in the dosing interval in critically ill patients. The concentration of unbound antibiotic in patients who are critically ill could fall to subtherapeutic concentrations and put patients at risk of treatment failure.^{35,36}

Importantly, increased severity of illness is associated with increased volume of distribution, so the most critically ill patients will probably have the least amount of antibiotic exposure if standard dosing is used, at least in the first days of treatment.²⁹ With recovery from infection, volume of distribution returns to normal and, for longer courses of therapy, dose modifications throughout treatment are often needed. For all antibiotic classes, which include concentration-dependent antibiotics, an increased volume of distribution might delay the time taken to reach therapeutic concentrations.

Antibiotics need to reach effective concentrations in the interstitial fluid of tissues, because this is the site of most infections.⁴⁴ However, severe infections can cause vascular dysfunctions such as microvascular failure, which can impair drug delivery into body tissues.⁴⁵ Several studies report impaired tissue penetration for various antibiotics in patients with severe infection. Antibiotics in these studies included cefpirome,⁴⁶ fosfomycin,⁴⁷ piperacillin,^{45,48} and levofloxacin,⁴⁹ and subtherapeutic concentrations in tissue for all these antibiotics are common in the early phase of treatment, particularly in patients with septic shock who are also receiving vasopressors.⁴⁵ Therefore, at least for the antibiotic classes above, plasma concentrations might be an imprecise surrogate for tissue concentrations.

Renal system

Many widely used antibiotics in critically ill patients are cleared renally, and therefore their concentrations will be affected by changes in renal function. Although standard practice is to reduce antibiotic doses in the presence of acute kidney injury to avoid toxic effects, some critically ill patients can develop augmented renal clearance where glomerular filtration is increased in some patients. Augmented renal clearance, defined as a creatinine clearance of at least 130 mL/min, is a potential reason for underdosing, and thus some critically ill patients with renal impairment might actually need more intensive regimens of antibiotics.

Augmented renal clearance is driven by pathophysiological responses to infection and treatment interventions (eg, fluid resuscitation and use of vasopressors) that are also associated with an early increase in cardiac output and enhanced blood flow to major organs.⁵⁰

Increased perfusion to the kidneys enhances drug delivery and therefore substantially raises glomerular filtration and clearance of renally cleared solutes, including some antibiotics, such as aminoglycosides, β lactams, and glycopeptides.^{1,51,52} Augmented renal clearance is frequently seen in critically ill patients with normal serum creatinine

concentrations, and typically happens in younger men (aged less than 55 years) with trauma, sepsis, burns, haematological malignant disease, or pancreatitis.⁵³ In an investigation by Udy and colleagues⁵⁴ up to 82% of patients with augmented renal clearance did not achieve therapeutic antibiotic concentrations with standard doses.

Any reduction in kidney perfusion, including micro-circulatory failure, could lead to acute kidney injury and reduced clearance of renally eliminated antibiotics. Acute kidney injury is identified by raised serum creatinine concentrations or a reduction in urine output⁵⁵ and necessitates an appropriate decrease in antibiotic dose to ensure therapeutic but non-toxic exposure. However, large dose reductions are not needed in the presence of acute kidney injury for drugs with a wide therapeutic index, cleared by several routes, and for which the proportion of clearance through the non-renal route is moderate to high (eg, ceftriaxone, flucloxacillin, and ciprofloxacin have both hepatic and renal clearance pathways).

If severe acute kidney injury occurs, renal replacement therapy could be prescribed for clearance of metabolic waste products or fluid removal. This therapy could consist of continuous renal replacement, or intermittent haemodialysis, or a hybrid form of both, such as sustained low-efficiency dialysis. Continuous renal replacement therapy is the most usual form used in critically ill patients, although hybrid forms are becoming more widely used. Important principles and factors of antibiotic dosing during renal replacement therapy have been discussed in detail in other papers,^{56,57} but in general, drugs with high volumes of distribution (more than 1 L/kg), lipophilic drugs, or drugs that are highly protein bound (more than 80%), or all three, are poorly eliminated by renal replacement therapy.⁵⁶

Sepsis in the presence of renal replacement therapy is associated with a 50% increased probability of death, compared with renal replacement therapy alone.⁵⁸ The increased risk might be partly attributable to the difficulties in antibiotic dosing in patients with sepsis. Renal replacement therapy delivery does not have a standard approach, with the exception of intermittent haemodialysis, therefore antibiotic clearance varies substantially with method and setting. Some reports have emphasised the challenges for dosing with vancomycin, ciprofloxacin, and β lactams, because 10–50% of critically ill patients in these studies did not achieve target antibiotic concentrations.^{59,60} Dosing of antibiotics should ideally be individualised to the patient, method of renal replacement therapy, and setting.

Pulmonary system

Pneumonia is the most common infection in critically ill patients and an important cause of morbidity and mortality in patients in intensive care units (especially as a complication of mechanical ventilation).⁶¹ Provision of optimum antibiotic exposure for ventilated patients with

hospital-acquired pneumonia might be a challenge, especially when various factors associated with the patients, pathological changes, and factors that can affect drug penetration to the site of infection are taken into account.⁶² Alveolar compartments such as epithelial lining fluid are thought to be the closest measurable site where extracellular pathogens accumulate, and thus optimum antibiotic concentrations in the epithelial lining fluid might determine therapeutic success.⁶² After systemic administration, an antibiotic first crosses the alveolar capillary barrier, then reaches and acts within the epithelial lining fluid. The passage across the alveolar capillary barrier could be affected by physicochemical (eg, lipophilicity) and pharmacokinetic characteristics (eg, level of protein-binding) of the antibiotic, and patient-specific characteristics (eg, inflammation or chronic lung disease, or both). The degree of epithelial lining fluid penetration for an antibiotic is characterised by the ratio of exposure in the epithelial lining fluid to exposure in the plasma.

In the context of antibiotic physicochemistry, the more lipophilic antibiotics (eg, fluoroquinolones, macrolides, and oxazolidinones) have an epithelial lining fluid to plasma exposure ratio of at least 1.^{63,64} Such high exposure ratios are not always seen for hydrophilic antibiotics, although ratios might be underestimated because of technical errors.^{63,65,66} Although blood concentrations of antibiotics might seem therapeutic, epithelial lining fluid concentrations might be insufficient, especially with reduced bacterial susceptibility. Therefore, for hydrophilic drugs, some investigators suggest the use of higher doses in patients with severe nosocomial pneumonia.^{67,68} Alternatively, use of different administration approaches such as extended or continuous infusion of β lactam antibiotics,^{63,65} or administration via nebulisation,⁶⁹ could be used to raise antibiotic concentrations in epithelial lining fluid.

Hepatic system

In severe sepsis and septic shock, hepatic dysfunction could reduce drug metabolism and clearance.^{70,71} However, few data are available to guide antibiotic dose adjustments in critically ill patients with liver dysfunction.⁷²

Challenge 2: reduced bacterial susceptibility to antibiotics

Knowledge of the minimum inhibitory concentration of an antibiotic against a pathogen is essential to calculate the dose of antibiotic needed. The minimum inhibitory concentration is a critical factor of the pharmacokinetic/pharmacodynamic relationship that defines how much antibiotic exposure is necessary to achieve a predefined pharmacokinetic/pharmacodynamic target that is associated with maximum effectiveness.

Infections in intensive care units are often caused by pathogens with higher minimum inhibitory concentrations than in other clinical settings.^{73,74} For example,

in a German study of predominantly Gram negative isolates⁷⁵, the minimum inhibitory concentrations of doripenem, meropenem, and imipenem needed to kill 90% of the pathogen were all greater in critically ill patients than in patients who were not critically ill (four times greater with doripenem, and eight times greater with meropenem and imipenem).⁷⁵ For an antibiotic, the pharmacokinetic exposure that is needed to achieve the pharmacokinetic/pharmacodynamic ratio threshold rises proportionally with increased minimum inhibitory concentration. For example, if vancomycin is given for health-care-associated pneumonia, a pharmacokinetic/pharmacodynamic target ratio of area under the concentration–time curve from 0 h to 24 h to minimum inhibitory concentration of 400 might be used.⁷⁶ In this case, if a methicillin resistant *Staphylococcus aureus* pathogen has a vancomycin minimum inhibitory concentration value of 0.5 mg/L, then an area under the curve (0–24 h) value of 200 mg/L/h is needed. This concentration could be achieved comfortably with a trough concentration of more than 10 mg/L. However, if the minimum inhibitory concentration is 2 mg/L, then an area under the curve (0–24 h) value of 800 mg/L/h is needed. This concentration would, in turn, need a trough concentration of more than 20–25 mg/L, which would substantially raise the risk of drug-related toxic effects. In the case of high minimum inhibitory concentrations, an alternative antibiotic or combination therapy might be needed.

This example shows some of the challenges that might prevent optimum dosing of antibiotics in the presence of bacteria with reduced susceptibility. Quantitative knowledge of antibiotic susceptibility will help to guide dosing needs in critically ill patients. Another difficulty is reduced bacterial susceptibility to widely used antibiotics, particularly in critically ill patients, and therefore regular surveillance is needed.⁷⁷ Surveillance programmes should report minimum inhibitory concentrations from intensive care units separately from those on regular wards because differences in antibiotic susceptibility are often seen between the two.^{73,74,78,79} Most laboratories routinely report bacterial susceptibility to antibiotics with the classifications susceptible, intermediate-susceptible, or resistant, which are based on minimum inhibitory concentration breakpoints (ie, at which a bacterium is deemed either susceptible or resistant to the specific antibiotic being used). Although this approach is suitable for many clinical situations because it unambiguously delineates when an antibiotic should not be given, it might not be suitable for critically ill patients with altered pharmacokinetic and antibiotic susceptibilities close to the breakpoint of intermediate or resistant. In such patients, the relevant pharmacokinetic/pharmacodynamic target might still not be achieved even if the bacterial organism's breakpoint is classified as susceptible for a particular antibiotic.⁸⁰ Therefore, minimum inhibitory concentration data for a pathogen

in specific patients are essential to accurately calculate the pharmacokinetic exposure needed to achieve the necessary pharmacokinetic/pharmacodynamic targets in that patient—local microbiology laboratories could be engaged to obtain these data.

Another important issue for treatment of infections in critically ill patients is that minimum inhibitory concentration breakpoints reported by groups such as the European Committee on Antimicrobial Susceptibility and Testing and the Clinical and Laboratory Standards Institute are frequently derived from antibiotic exposures in patients who are not critically ill. If the pharmacokinetics for an individual patient are profoundly changed, and the patient is infected by a pathogen with a minimum inhibitory concentration at or near the resistant breakpoint, then a standard fixed regimen could increase the probability of underdosing.

In view of such inherent challenges for antibiotic dosing related to pathophysiology, pharmacokinetics, and reduced bacterial susceptibility, what can be done to possibly strengthen the probability of positive treatment outcomes with antibiotics for critically ill patients?

Possible solution: individualised antibiotic dosing for critically ill patients

Approaches

Best possible outcomes for patients from treatment of infection are most likely when pharmacokinetic/pharmacodynamic targets associated with maximum antibiotic activity are achieved. In-vitro and in-vivo mathematical pharmacokinetic/pharmacodynamic models introduced since the 1980s have enabled an accurate description of the targets that are associated with maximum antibiotic effect. Clinical analyses have attempted to support the results of these studies and have, for the most part, described pharmacokinetic/pharmacodynamic targets that do not differ from targets noted in the preclinical studies.⁸¹ Various targets that have been described in preclinical and clinical studies could be therapeutic targets for optimised dosing in individual patients (table 1).

To increase the probability of achieving therapeutic targets for antibiotics given systemically, two main approaches could be used to adjust standard regimens: altered administration techniques such as once daily dosing or prolonged infusion, which are often based on reported studies of the specific dosing regimen, or dose adjustment guided by therapeutic drug monitoring, or both approaches together.

Improved administration techniques

Many pharmacokinetic studies have applied dosing simulations to identify optimised regimens that can achieve pharmacokinetic/pharmacodynamic targets for infections caused by organisms with higher than normal minimum inhibitory concentrations, or for patients with altered pharmacokinetics. Such an approach to dosing is not individualised when used in a population, but it is a

form of therapeutic adaptation designed to improve antibiotic effectiveness. Dosing based on pharmacokinetic/pharmacodynamic models has changed the way aminoglycosides are prescribed clinically, from three times to once per day, and has improved the safety and effectiveness of these compounds.¹¹⁵ Because of this improvement, extended-interval dosing for aminoglycosides is widely regarded as the standard of antibiotic care.¹¹⁶

Several studies of β lactams have been reported, the results of which collectively suggest that infusion of β lactams should be extended in patients who are critically ill (either for 40–50% of the dosing interval [ie, 3–4 h], or a continuous infusion), because this practice is more likely to achieve pharmacokinetic/pharmacodynamic targets than standard bolus dosing.^{68,117–124} Some studies investigated the clinical value of extended infusions in prospective randomised controlled trials. The results suggest that a continuous infusion of antibiotics is advantageous for critically ill patients with severe sepsis.^{125,126} Although some meta-analyses of these studies have not been able to quantify definitive advantages for either intermittent or extended infusions of β lactams, these studies have often not been stratified for patients with altered pharmacokinetics or reduced susceptibility.^{126,127} For example, an investigation by Arnold and colleagues¹²⁸ changed dosing of β lactams across an intensive care unit from intermittent infusion to extended infusion, but noted this approach was not clinically advantageous. This result was probably because of the high proportion of susceptible pathogens in that particular intensive care unit with low minimum inhibitory concentrations, which meant that standard infusions had already obtained requisite pharmacokinetic/pharmacodynamic ratio thresholds in most patients.¹²⁸ Clinicians should find out whether patients, pathogens, or both, might not respond to a standard fixed regimen, because a different approach to dosing for all patients might not be necessary or confer any therapeutic advantage. In a separate investigation by Lodise and colleagues,¹²⁹ extended infusions of piperacillin–tazobactam for *Pseudomonas aeruginosa* infections were clinically effective in patients who were critically ill with very severe sickness.

A few studies of vancomycin have compared continuous infusion versus intermittent dosing and the results have mostly shown equivalence between the two techniques.¹³⁰ Results from one study only, by Rello and colleagues,¹³¹ have shown potential clinical outcome advantages for continuous versus intermittent infusion of vancomycin. The merit of continuous infusion for vancomycin is probably related to more consistent achievement of pharmacokinetic/pharmacodynamic targets,³¹ although the effect of continuous infusion of antibiotics on antibiotic resistance has not been addressed in these studies.

In general, a change in the dose, frequency, or method of administration of an antibiotic can be implemented

For the European Committee on Antimicrobial Susceptibility and Testing see <http://www.eucast.org>

For the Clinical and Laboratory Standards Institute see <http://www.clsi.org>

Preclinical studies			Clinical studies	
Concentration-dependent				
Aminoglycosides	Maximum killing ⁴³ Resistance suppression ⁸⁷	AUC_{0-24}/MIC 80–100 C_{max}/MIC 10–30	Clinical cure ^{82–86} Microbiological cure	C_{max}/MIC 8–10; $AUC/MIC >70$..
Time-dependent				
Carbapenems	Maximum killing ⁸⁸ Resistance suppression ^{90, 91}	40% $T_{>MIC}$ $16 \times MIC$; $C_{min}/MIC >6-2$	Clinical cure ⁸⁹ Microbiological cure ⁹⁷	75% $T_{>MIC}$; $C_{min}/MIC \geq 5$ 54% $T_{>MIC}$
Cephalosporins	Maximum killing ¹¹ Resistance suppression	60–70% $T_{>MIC}$..	Clinical cure ⁹² Microbiological cure ^{16,93}	100% $T_{>MIC}$ $60-100\% T_{>MIC}$; 95% $T_{>4-3MIC}$
Penicillins	Maximum killing ¹¹ Resistance suppression ⁹⁴	40–50% $T_{>MIC}$ 40–50% $T_{>MIC}$	Clinical cure Microbiological cure ⁹⁵	.. 40–50% $T_{>MIC}$
Concentration-dependent and time-dependent				
Fluoroquinolones	Maximum killing ^{11,96} Resistance suppression ^{99,100,101}	$AUC_{0-24}/MIC >30-100$ $AUC_{0-24}/MIC >160$; $AUC_{0-24}/MPC \geq 22$	Clinical cure ^{15,86,96,97,98} Microbiological cure ^{14,86,102}	$AUC_{0-24}/MIC \geq 125-250$; $C_{min}/MIC \geq 8$ $AUC_{0-24}/MIC \geq 34-125$; $C_{min}/MIC \geq 8$
Vancomycin	Maximum killing ¹⁰³ Resistance suppression ¹⁰⁴	AUC_{0-24}/MIC 86–460 $AUC_{0-24}/MIC >200$	Clinical cure ^{20,21} Microbiological cure ²⁰	$AUC_{0-24}/MIC \geq 400-450$ $AUC_{0-24}/MIC \geq 400$
Linezolid	Maximum killing Resistance suppression	Clinical cure ²² Microbiological cure ²²	$AUC_{0-24}/MIC \geq 85$; 85% $T_{>MIC}$ AUC_{0-24}/MIC 80–120; 85% $T_{>MIC}$
Tigecycline	Maximum killing ¹⁰⁵ Resistance suppression	50% $T_{>MIC}$..	Clinical cure ^{106,107,108} Microbiological cure ^{109,110}	$AUC_{0-24}/MIC >12.8-17.9$; $fAUC_{0-24}/MIC \geq 0.9$ AUC_{0-24}/MIC 6.9–17.9
Daptomycin	Maximum killing ^{111,112} Resistance suppression ¹⁰⁴	AUC_{0-24}/MIC 38–442 $AUC_{0-24}/MIC >200$	Clinical cure Microbiological cure
Colistin	Maximum killing ^{113,114} Resistance suppression	AUC_{0-24}/MIC 7–23 ..	Clinical cure Microbiological cure

AUC_{0-24}/MIC =ratio of area under the concentration time curve from 0 to 24 h to minimum inhibitory concentration. C_{min}/MIC =ratio of maximum concentration of antibiotic in a dosing interval to minimum inhibitory concentration. $T_{>MIC}$ =percentage of dosing interval that the antibiotic concentration is maintained above the minimum inhibitory concentration. AUC_{0-24}/MPC =ratio of the AUC_{0-24} to the concentration that prevents mutation. C_{min} =minimum concentration of antibiotic in a dosing interval, f =free concentration or fraction of drug not bound to plasma proteins. *Where the index is reported as a range, data included might have been derived from different infection models with different bacteria. Specific data for the contributing values can be found in the associated references. Data for the various indices has been reported in different studies according to total and free (unbound) concentrations of drug.

Table 1: Studies reporting pharmacokinetic/pharmacodynamic indices from preclinical and clinical assessments, by antibiotic class

Table 1: Studies reporting pharmacokinetic/pharmacodynamic indices from preclinical and clinical assessments, by antibiotic class

across an intensive care unit when minimum inhibitory concentration data are available to justify an empirical change.

Adjustment of antibiotic dose guided by therapeutic drug monitoring

Therapeutic drug monitoring is traditionally used to minimise toxic effects, but in critically ill patients it is also used to optimise dosing in the presence of severely changed pharmacokinetics.^{10,132} Therapeutic drug monitoring relies on direct measurement of serum antibiotic concentrations with timely feedback to clinicians who then interpret results in the context of therapeutic ranges. Adequacy of a measured concentration can be interpreted by either direct comparison of one concentration value to a therapeutic target, or an estimation of antibiotic exposure with non-linear regression or Bayesian techniques. Doses could then be increased or decreased as predicted by the clinician or any dosing software used.

The concentration of unbound drug in a blood sample is important for accurate interpretation of drug exposure, because only free drug is microbiologically active. Knowledge of free concentrations is most important for antibiotics that are highly bound in plasma.¹³³ Likewise, concentration results should be made available in a

timely manner so that rapid dose adjustments can be made. In view of the dynamic nature of pharmacokinetics in patients who are critically ill, long delays can result in inappropriate dose adjustment. For ideal therapeutic drug monitoring, the antibiotic minimum inhibitory concentration values for the organism and pharmacokinetic targets should be available too.

So far, various reports of therapeutic drug monitoring for antibiotics in patients who are critically ill include investigations of aminoglycosides,¹³⁴ glycopeptides,¹³⁵ β lactams,^{10,19,136} linezolid,¹³⁷ and quinolones.¹⁰ However, few studies have compared the clinical outcomes of therapeutic drug monitoring versus outcomes without this intervention, and therefore prospective individualised therapy in patients who are critically ill should be rigorously assessed.

Dosing nomograms for dose adjustment of antibiotics are widely used across many clinical specialties.¹³⁸ These nomograms compare a measured concentration of prescribed antibiotic at a particular timepoint with a graph that shows the therapeutic range of concentrations at the same timepoint. The dose of antibiotic can then be increased or reduced as necessary to ensure the next measured concentration is in the therapeutic range. These nomograms are simple to use and are popular with clinicians. Nomograms for vancomycin and

aminoglycosides are the most widely available^{138–140} because these drugs have high toxicity thresholds (ie, low therapeutic index) and available assays, and they are often targets for therapeutic drug monitoring by pharmacists and physicians. A limitation of many nomograms, however, is that they are rarely designed with pharmacokinetic/pharmacodynamic targets from patients who are critically ill, and rely on clinicians' experience to make appropriate dose adjustments in these circumstances.¹⁴¹

Application of non-linear regression analysis to a series of concentration values at different timepoints can be used to calculate basic pharmacokinetic variables such as area under the curve, clearance, elimination rate constant, maximum concentration in the dosing interval, and trough concentration. To calculate the dose of an antibiotic, the measured or calculated values for area under the concentration–time curve, maximum concentration of antibiotic in a dosing interval or trough concentrations, or both, can be compared against the pharmacokinetic/pharmacodynamic targets for the prescribed antibiotic, and the dose empirically increased or decreased as needed.

Population pharmacokinetic models have been developed for many antibiotics used in patients who are

critically ill. A drawback of many of these models is that the increased pharmacokinetic variability in these patients is unlikely to be captured because the sample size used in many of these studies is usually too small (around ten to 20 patients).^{142,143} However, these population models are probably more accurate than a model derived from another group of patients.¹⁴⁴

Greatest accuracy of dose adaptation based on data for drug concentrations could be ensured with a stochastic control approach, to define the timing and number of samples that should be taken from a patient and then used in dose prediction.¹⁴⁵ This approach is particularly useful for drugs with high pharmacokinetic variability such as voriconazole.⁷² The accuracy of dose prediction improves with more data for antibiotic concentrations across different dosing intervals.⁷²

In Bayesian dose adaptation, the dose of a drug is adjusted to ensure an individual patient's exposure meets pharmacokinetic/pharmacodynamic targets. Information about a specific patient's serum drug concentrations and a population pharmacokinetic model from the relevant population are included. The model contains a series of mathematical equations that include parameter estimates and their distribution for clearance, and volume of distribution.

	BestDose v1.0	ID-ODS	MWPPharm	DoseMe	TCI Works	First-dose	WinAUC	CADDy Program v4.e
Method of pharmacokinetic assessment	Bayesian non-parametric approach	Bayesian parametric approach	Bayesian parametric approach	Bayesian parametric approach	Bayesian parametric approach	Population parametric approach	Non-linear regression	Non-linear regression
Adaptive feedback?	Yes	Yes	Yes	Yes	Yes	No	No	No
Web, server, or terminal based?	Terminal	Terminal and server	Terminal and server	Terminal and server	Terminal and server	Web	Terminal	Web or server
Compatibility	Windows	Mac, Windows, Linux, Android, iOS	Windows	Mac, Windows, Linux, Android, iOS	Mac, Windows	Mac, Windows, Linux, Android, iOS	Windows	Mac, Windows, Linux, Android, iOS
Smart phone application?	No	Yes	No	Yes	No	Yes	No	No
Patient covariates in dose predictions?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Output from program?	Doses and pharmacokinetic parameter estimates	Dosing regimens, pharmacokinetic parameter estimates, and PTAs	Doses and pharmacokinetic parameter estimates	Doses and pharmacokinetic parameter estimates	Doses and pharmacokinetic parameter estimates	Doses	Pharmacokinetic parameter estimates	Doses
IT support available within 24 h?*	Yes	Yes	No	Yes	Yes	No	No	Yes
Capacity for ICU and non-ICU dosing?	Yes	Yes	Yes	Yes	Yes	No	No	No
Further information	http://www.lapk.org	http://www.optimum-dosing-strategies.org	http://www.mediware.cz/index_en.html	www.doseme.com.au	www.tciworks.info	http://www.firstdose.org/	Contact the developers (Dr Jerome Schentag: schentag@buffalo.edu)	www.jjpreisenberger.de
Cost	Current version is free.	Free	€1250 per license	Dependent on requirements	Free	Free	Free	Free

ICU=intensive care unit. IT=information technology. PTA=probability of target attainment. ID-ODS=Individually Designed Optimum Dosing Strategies. WinAUC=Windows Antibiotic Utilisation Information and Consultation. *Response time often depends on the severity of the problem for the user (for non-urgent issues, responses might exceed 24 h).

Table 2: Characteristics of various antibiotic dosing programs

A critically ill patient could receive the first dose at the clinician's discretion, preferably with a strategy that is likely to achieve pharmacokinetic and pharmacodynamic targets (eg, **vancomycin loading dose**³¹ or **extended infusion β lactam**).^{68,117–124} During the first or subsequent dose intervals, one or more blood samples could be taken to estimate the patient's pharmacokinetic variables for the antibiotic. Samples could then be assayed in a timely manner (eg, within 6 h) and, if a **software package** has been chosen to help to **calculate** antibiotic dosing, then the dosing history, drug concentrations, pathogen minimum inhibitory concentration, and necessary data for the patient (eg, weight or creatinine clearance) could be entered. The software could then **combine** the recorded **data** for the **patient** plus the **population** pharmacokinetic model to **estimate** the **Bayesian** posterior **pharmacokinetic parameter values**. The appropriate dose that achieves the pharmacokinetic/pharmacodynamic targets needed for that particular patient could then be **calculated** and **used** in the next dosing interval.

Many programs are available that apply different approaches to calculate individualised antibiotic doses for patients. Table 2 shows a summary of various programs, and others are identified by Fuchs and colleagues.¹⁴⁶ Importantly, **not all programs contain all relevant antibiotics**, although the developers of most state that additional pharmacokinetic models for antibiotics can be included. To ensure that robust antibiotic dosing at the bedside is possible, many of these programs have, or will have, electronic medical record interfaces and **smart-phone applications** that can be used at the patient's bedside.

On the basis of best available evidence, **we suggest the following process for dose individualisation in a critically ill patient**: (1) **diagnose the infection** and select an antibiotic; (2) **establish the patient's physiological characteristics** (eg, **weight**, **sex**, **creatinine clearance**, **serum albumin** concentration, **fluid overload** status, **presence of extracorporeal circuits**); (3) **estimate the first dose** of antibiotic on the **basis** of the patient's characteristics and local baseline data for **bacterial susceptibility** in the intensive care unit, possibly with the appropriate software; (4) **give the dose to the patient in a timely manner** after diagnosis; and (5) **take blood samples at predefined timepoints** and assess them in a timely manner.

The clinician could then enter the concentration–time data from the blood samples and patient's covariate data into software that personalises a dosing regimen for the patient to achieve an evidence-based pharmacokinetic and pharmacodynamic target. When available, susceptibility data for a specific pathogen should be incorporated into the dose estimation process.

Conclusions

Patients who are critically ill have substantially varied pharmacokinetics compared with patients who are not critically ill. Additionally, patients who are critically ill

Search strategy and selection criteria

We searched for English language articles in PubMed (1966 to Feb 2014), Embase (1966 to Feb 2014), the Cochrane Controlled Trial Register, and references from relevant articles, with the key words “antibacterial”, “Bayesian”, “intensive care unit”, “pharmacodynamics”, and “pharmacokinetics”. Search terms related to antibiotic pharmacokinetics and pharmacodynamics in patients who were critically ill, and dosing software, were also included.

are more likely to be infected by bacteria that are less susceptible to antibiotic treatment. Traditional strategies for dosing with antibiotics in patients who are critically ill are unlikely to consistently achieve the pharmacokinetic/pharmacodynamic targets associated with maximum antibiotic activity. This situation raises the risk of clinical failure, or development of resistance, or both, for a patient who is critically ill. Optimisation of antibiotic dosing in the intensive care unit therefore needs an individualised approach for the patient that takes into account the minimum inhibitory concentration of an antibiotic for the infecting pathogen, and selects a dosing regimen that is likely to obtain the requisite pharmacokinetic/pharmacodynamic ratio predictive of success. Proactive therapeutic management for antibiotics other than vancomycin and aminoglycosides is possible, but should be escalated to the next level and made available to all hospitals. Individualised antibiotic concentrations for patients, combined with software programs that calculate individual doses, could increase the accuracy of antibiotic dosing, and the likelihood that pharmacokinetic and pharmacodynamic targets and favourable clinical outcomes can be achieved in all patients.

Contributors

JAR, JLK, and UT contributed to conception of the Review. JAR and MHA-A were responsible for the literature search, and drafting the tables and figure. JAR, JLK, UT, and MHA-A wrote the manuscript. JL, JWM, AAV, TWF, WWH, AF, MNN, JJS, GD, and ORF were responsible for critical review. All authors contributed to data interpretation and final approval of the Review.

Declaration of interests

AF is involved in the development of the software Individually Designed Optimum Dosing Strategies (ID-ODS). MNN is involved in the development of the software BestDose. JJS is involved in the development of the software WinAUC. ORF is involved in the development of the software CADDy Program. No other authors have competing interests.

Acknowledgments

Judit Preisenberger, Alexander Brinkman, Robert McLeay, Nick Holford, and Sam Holford provided information about specific dosing software programs. JAR is funded by a career development fellowship from the National Health and Medical Research Council of Australia (APP1048652). TWF is a UK Medical Research Council (MRC) Clinical Training Fellow supported by the North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics, which is funded by the MRC (grant number G1000417/94909), ICON, GlaxoSmithKline, AstraZeneca, and the Medical Evaluation Unit. WWH is supported by a National Institute of Health Clinician Scientist Fellowship.

References

- 1 Lipman J, Udy AA, Roberts JA. Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story. *Anaesth Intensive Care* 2011; **39**: 999–1000.
- 2 Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. *Crit Care Med* 2009; **37**: 840–51, quiz 859.
- 3 Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. *Crit Care Med* 2007; **35**: 1244–50.
- 4 Bellomo R, Cass A, Cole L, et al, and the RENAL Replacement Therapy Study Investigators. Intensity of continuous renal-replacement therapy in critically ill patients. *N Engl J Med* 2009; **361**: 1627–38.
- 5 Finfer S, Chittock DR, Su SY, et al, and the NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009; **360**: 1283–97.
- 6 Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. *Chest* 1999; **115**: 462–74.
- 7 Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Crit Care Med* 2006; **34**: 1589–96.
- 8 MacArthur RD, Miller M, Albertson T, et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. *Clin Infect Dis* 2004; **38**: 284–88.
- 9 Ranieri VM, Thompson BT, Barie PS, et al, and the PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. *N Engl J Med* 2012; **366**: 2055–64.
- 10 Scaglione F, Esposito S, Leone S, et al. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. *Eur Respir J* 2009; **34**: 394–400.
- 11 Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. *Clin Infect Dis* 1998; **26**: 1–10.
- 12 Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. *Nat Rev Microbiol* 2004; **2**: 289–300.
- 13 van Lent-Evers NA, Mathôt RA, Geus WP, van Hout BA, Vinks AA. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. *Ther Drug Monit* 1999; **21**: 63–73.
- 14 Ambrose PG, Grasela DM, Grasela TH, Passarelli J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against *Streptococcus pneumoniae* in patients with community-acquired respiratory tract infections. *Antimicrob Agents Chemother* 2001; **45**: 2793–97.
- 15 Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. *Antimicrob Agents Chemother* 1993; **37**: 1073–81.
- 16 Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of cefepime in patients infected with *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2010; **54**: 1111–16.
- 17 Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. *Antimicrob Agents Chemother* 2007; **51**: 1725–30.
- 18 Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. *J Antimicrob Chemother* 2013; **68**: 900–06.
- 19 Roberts JA, Uldemolins M, Roberts MS, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. *Int J Antimicrob Agents* 2010; **36**: 332–39.
- 20 Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with *Staphylococcus aureus* lower respiratory tract infections. *Clin Pharmacokinet* 2004; **43**: 925–42.
- 21 Zelenitsky S, Rubinstein E, Ariano R, et al, and the Cooperative Antimicrobial Therapy of Septic Shock-CATSS Database Research Group. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant *Staphylococcus aureus*-associated septic shock. *Int J Antimicrob Agents* 2013; **41**: 255–60.
- 22 Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. *Clin Pharmacokinet* 2003; **42**: 1411–23.
- 23 Roberts JA, De Waele JJ, Dimopoulos G, et al. DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. *BMC Infect Dis* 2012; **12**: 152.
- 24 Roberts JA, Paul SK, Akova M, et al, and the DALI Study Authors. DALI: Defining Antibiotic Levels in Intensive care unit patients: Are current beta-lactam antibiotic doses sufficient for critically ill patients? *Clin Infect Dis* Feb 28, 2014; <http://www.ncbi.nlm.nih.gov/pubmed/24429437>
- 25 van der Poll T. Immunotherapy of sepsis. *Lancet Infect Dis* 2001; **1**: 165–74.
- 26 Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β -lactams. *Crit Care* 2011; **15**: R206.
- 27 Gous A, Lipman J, Scribante J, et al. Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. *Int J Antimicrob Agents* 2005; **26**: 50–55.
- 28 Conil JM, Georges B, Breden A, et al. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. *Int J Antimicrob Agents* 2006; **28**: 226–30.
- 29 Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. *Anaesth Intensive Care* 1993; **21**: 172–73.
- 30 Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA. Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. *Ann Intensive Care* 2012; **2**: 35.
- 31 Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. *Antimicrob Agents Chemother* 2011; **55**: 2704–09.
- 32 Buerger C, Plock N, Dehghanyar P, Joukhadar C, Kloft C. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. *Antimicrob Agents Chemother* 2006; **50**: 2455–63.
- 33 Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, and the SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med* 2004; **350**: 2247–56.
- 34 Uldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibiotic dosing in critically ill patients. *Clin Pharmacokinet* 2011; **50**: 1–12.
- 35 Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. *Clin Pharmacokinet* 2013; **52**: 1–8.
- 36 Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. *J Antimicrob Chemother* 2001; **47**: 421–29.
- 37 Uldemolins M, Roberts JA, Wallis SC, Rello J, Lipman J. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. *J Antimicrob Chemother* 2010; **65**: 1771–78.
- 38 Brink AJ, Richards GA, Schillack V, Kiem S, Schentag J. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. *Int J Antimicrob Agents* 2009; **33**: 432–36.
- 39 Burkhardt O, Kumar V, Katterwe D, et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. *J Antimicrob Chemother* 2007; **59**: 277–84.
- 40 Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. *Antimicrob Agents Chemother* 2004; **48**: 2799–807.
- 41 Mouton JW, Jacobs N, Tiddens H, Horrevorts AM. Pharmacodynamics of tobramycin in patients with cystic fibrosis. *Diagn Microbiol Infect Dis* 2005; **52**: 123–27.
- 42 Mouton JW, van Ogtrop ML, Andes D, Craig WA. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. *Antimicrob Agents Chemother* 1999; **43**: 2473–78.

- 43 Vogelmann B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. *J Infect Dis* 1988; **158**: 831–47.
- 44 Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. *J Antimicrob Chemother* 1993; **31** (suppl D): 1–16.
- 45 Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. *Crit Care Med* 2001; **29**: 385–91.
- 46 Joukhadar C, Klein N, Mayer BX, et al. Plasma and tissue pharmacokinetics of ceftiofime in patients with sepsis. *Crit Care Med* 2002; **30**: 1478–82.
- 47 Joukhadar C, Klein N, Dittich P, et al. Target site penetration of fosfomycin in critically ill patients. *J Antimicrob Chemother* 2003; **51**: 1247–52.
- 48 Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis—bolus versus continuous administration? *Crit Care Med* 2009; **37**: 926–33.
- 49 Zeitlinger MA, Dehghanyar P, Mayer BX, et al. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. *Antimicrob Agents Chemother* 2003; **47**: 3548–53.
- 50 Di Giamtomasso D, May CN, Bellomo R. Vital organ blood flow during hyperdynamic sepsis. *Chest* 2003; **124**: 1053–59.
- 51 Lipman J, Wallis SC, Boots RJ. Cefepime versus ceftiofime: the importance of creatinine clearance. *Anesth Analg* 2003; **97**: 1149–54.
- 52 Udy AA, Roberts JA, Lipman J. Implications of augmented renal clearance in critically ill patients. *Nat Rev Nephrol* 2011; **7**: 539–43.
- 53 Fuster-Lluch O, Gerónimo-Pardo M, Peyró-García R, Lizán-García M. Glomerular hyperfiltration and albuminuria in critically ill patients. *Anaesth Intensive Care* 2008; **36**: 674–80.
- 54 Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial β -lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. *Chest* 2012; **142**: 30–39.
- 55 Bagshaw SM, George C, Dinu I, Bellomo R. A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. *Nephrol Dial Transplant* 2008; **23**: 1203–10.
- 56 Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. *Crit Care Med* 2009; **37**: 2268–82.
- 57 Jamal JA, Economou CJ, Lipman J, Roberts JA. Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. *Curr Opin Crit Care* 2012; **18**: 460–71.
- 58 Bagshaw SM, Uchino S, Bellomo R, et al, and the Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. *Clin J Am Soc Nephrol* 2007; **2**: 431–39.
- 59 Roberts DM, Roberts JA, Roberts MS, et al, and the RENAL Replacement Therapy Study Investigators. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. *Crit Care Med* 2012; **40**: 1523–28.
- 60 Seyler L, Cotton F, Taccone FS, et al. Recommended β -lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. *Crit Care* 2011; **15**: R137.
- 61 Vincent JL, Rello J, Marshall J, et al, and the EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. *JAMA* 2009; **302**: 2323–29.
- 62 Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. *Clin Pharmacokinet* 2011; **50**: 637–64.
- 63 Boselli E, Breilh D, Duflo F, et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. *Crit Care Med* 2003; **31**: 2102–06.
- 64 Kontou P, Chatzika K, Pitsiou G, Stanopoulos I, Argyropoulou-Pataka P, Kioumis I. Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. *Antimicrob Agents Chemother* 2011; **55**: 4149–53.
- 65 Boselli E, Breilh D, Rimmelé T, et al. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. *Crit Care Med* 2008; **36**: 1500–06.
- 66 Boselli E, Breilh D, Rimmelé T, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. *Intensive Care Med* 2004; **30**: 989–91.
- 67 Boselli E, Breilh D, Cannesson M, et al. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. *Intensive Care Med* 2004; **30**: 976–79.
- 68 Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. *Antimicrob Agents Chemother* 2011; **55**: 1606–10.
- 69 Lu Q, Luo R, Bodin L, et al, and the Nebulized Antibiotics Study Group. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. *Anesthesiology* 2012; **117**: 1335–47.
- 70 McKindley DS, Hanes S, Boucher BA. Hepatic drug metabolism in critical illness. *Pharmacotherapy* 1998; **18**: 759–78.
- 71 Uldemolins M, Roberts JA, Lipman J, Rello J. Antibiotic dosing in multiple organ dysfunction syndrome. *Chest* 2011; **139**: 1210–20.
- 72 Hope WW, Vanguilder M, Donnelly JP, et al. Software for dosage individualization of voriconazole for immunocompromised patients. *Antimicrob Agents Chemother* 2013; **57**: 1888–94.
- 73 Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). *Diagn Microbiol Infect Dis* 2006; **56**: 57–62.
- 74 Samtani MN, Flamm R, Kaniga K, Nandy P. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. *Antimicrob Agents Chemother* 2010; **54**: 2360–64.
- 75 Valenza G, Seifert H, Decker-Burgard S, Laeuffer J, Morrissey I, Muters R, and the COMPACT Germany Study Group. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany. *Int J Antimicrob Agents* 2012; **39**: 255–58.
- 76 Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. *Clin Infect Dis* 2009; **49**: 325–27.
- 77 Patzer JA, Dzierzanowska D, Turner PJ. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997–2007). *J Antimicrob Chemother* 2008; **62**: 369–75.
- 78 Binkley S, Fishman NO, LaRosa LA, et al. Comparison of unit-specific and hospital-wide antibiograms: potential implications for selection of empirical antimicrobial therapy. *Infect Control Hosp Epidemiol* 2006; **27**: 682–87.
- 79 Lee K, Kim MN, Kim JS, et al, and the KONSAR Group. Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of *Acinetobacter* spp. and *P. aeruginosa* in Korea: KONSAR study 2009. *Yonsei Med J* 2011; **52**: 793–802.
- 80 Gillespie EL, Kuti JL, Nicolau DP. When “S” does not mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection. *Conn Med* 2005; **69**: 203–10.
- 81 Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. *Clin Infect Dis* 2007; **44**: 79–86.
- 82 Kashuba ADM, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. *Antimicrob Agents Chemother* 1999; **43**: 623–29.
- 83 Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. *J Infect Dis* 1987; **155**: 93–99.
- 84 Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. *Clin Infect Dis* 2007; **45**: 753–60.

- 85 Highet VS, Forrest A, Ballow CH, Schentag JJ. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. *J Antimicrob Chemother* 1999; **43** (suppl A): 55–63.
- 86 Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE. Treatment and outcome of *Pseudomonas aeruginosa* bacteraemia: an antibiotic pharmacodynamic analysis. *J Antimicrob Chemother* 2003; **52**: 668–74.
- 87 Tam VH, Ledesma KR, Vo G, Kabbara S, Lim TP, Nikolaou M. Pharmacodynamic modeling of aminoglycosides against *Pseudomonas aeruginosa* and *Acinetobacter baumannii*: identifying dosing regimens to suppress resistance development. *Antimicrob Agents Chemother* 2008; **52**: 3987–93.
- 88 Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against *Pseudomonas aeruginosa* expressing MexA-MexB-OprM efflux pumps. *Diagn Microbiol Infect Dis* 2007; **57**: 153–61.
- 89 Ariano RE, Nyhlén A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. *Ann Pharmacother* 2005; **39**: 32–38.
- 90 Tam VH, Schilling AN, Melnick DA, Coyle EA. Comparison of beta-lactams in counter-selecting resistance of *Pseudomonas aeruginosa*. *Diagn Microbiol Infect Dis* 2005; **52**: 145–51.
- 91 Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2005; **49**: 4920–27.
- 92 McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. *Int J Antimicrob Agents* 2008; **31**: 345–51.
- 93 Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with Gram-negative infections. *J Antimicrob Chemother* 2002; **50**: 425–28.
- 94 Knudsen JD, Odenholt I, Erlendsdottir H, et al. Selection of resistant *Streptococcus pneumoniae* during penicillin treatment in vitro and in three animal models. *Antimicrob Agents Chemother* 2003; **47**: 2499–506.
- 95 Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. *Pediatr Infect Dis J* 1996; **15**: 255–59.
- 96 Zelenitsky SA, Ariano RE. Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection. *J Antimicrob Chemother* 2010; **65**: 1725–32.
- 97 Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. *JAMA* 1998; **279**: 125–29.
- 98 Peloquin CA, Cumbo TJ, Nix DE, Sands MF, Schentag JJ. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. *Arch Intern Med* 1989; **149**: 2269–73.
- 99 Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. *J Clin Invest* 2003; **112**: 275–85.
- 100 Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GL. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on *Pseudomonas aeruginosa*. *J Infect Dis* 2005; **192**: 420–28.
- 101 Olofsson SK, Marcusson LL, Komp Lindgren P, Hughes D, Cars O. Selection of ciprofloxacin resistance in *Escherichia coli* in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. *J Antimicrob Chemother* 2006; **57**: 1116–21.
- 102 Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. *J Infect Dis* 2004; **189**: 1590–97.
- 103 Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. *Infect Dis Clin North Am* 2003; **17**: 479–501.
- 104 Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH. Testing the mutant selection window hypothesis with *Staphylococcus aureus* exposed to daptomycin and vancomycin in an in vitro dynamic model. *J Antimicrob Chemother* 2006; **58**: 1185–92.
- 105 van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycolylglycyls (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. *Antimicrob Agents Chemother* 2000; **44**: 943–49.
- 106 Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/pharmacodynamic profile for tigecycline—a new glycolylglycyl antimicrobial agent. *Diagn Microbiol Infect Dis* 2005; **52**: 165–71.
- 107 Rubino CM, Bhavnani SM, Forrest A, et al. Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia. *Antimicrob Agents Chemother* 2012; **56**: 130–36.
- 108 Bhavnani SM, Rubino CM, Hammel JP, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. *Antimicrob Agents Chemother* 2012; **56**: 1065–72.
- 109 Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. *Clin Infect Dis* 2005; **41** (suppl 5): S333–40.
- 110 Passarell JA, Meagher AK, Liolios K, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. *Antimicrob Agents Chemother* 2008; **52**: 204–10.
- 111 Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP. Pharmacodynamic profile of daptomycin against *Enterococcus* species and methicillin-resistant *Staphylococcus aureus* in a murine thigh infection model. *J Antimicrob Chemother* 2003; **52**: 405–11.
- 112 Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. *Antimicrob Agents Chemother* 2004; **48**: 63–68.
- 113 Dudhani RV, Turnidge JD, Coulthard K, et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against *Pseudomonas aeruginosa* in murine thigh and lung infection models. *Antimicrob Agents Chemother* 2010; **54**: 1117–24.
- 114 Dudhani RV, Turnidge JD, Nation RL, Li J. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against *Acinetobacter baumannii* in murine thigh and lung infection models. *J Antimicrob Chemother* 2010; **65**: 1984–90.
- 115 Marik PE, Lipman J, Kobilski S, Scribante J. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. *J Antimicrob Chemother* 1991; **28**: 753–64.
- 116 Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. *J Antimicrob Chemother* 1996; **37**: 645–63.
- 117 Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. *Intensive Care Med* 2011; **37**: 632–38.
- 118 Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. *Clin Infect Dis* 2003; **36** (suppl 1): S42–50.
- 119 Lodise TP Jr, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. *Antimicrob Agents Chemother* 2004; **48**: 4718–24.
- 120 Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. *Antimicrob Agents Chemother* 2005; **49**: 461–63.
- 121 Nicasio AM, Ariano RE, Zelenitsky SA, et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. *Antimicrob Agents Chemother* 2009; **53**: 1476–81.
- 122 Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. *Int J Antimicrob Agents* 2001; **17**: 497–504.
- 123 Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. *Int J Antimicrob Agents* 2010; **35**: 156–63.

- 124 Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. *Crit Care Med* 2013; **41**: 489–95.
- 125 Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. *Clin Infect Dis* 2013; **56**: 236–44.
- 126 Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. *Crit Care Med* 2009; **37**: 2071–78.
- 127 Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. *Lancet Infect Dis* 2005; **5**: 581–89.
- 128 Arnold HM, Hollands JM, Skrupky LP, et al. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study. *Ann Pharmacother* 2013; **47**: 170–80.
- 129 Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for *Pseudomonas aeruginosa* infection: clinical implications of an extended-infusion dosing strategy. *Clin Infect Dis* 2007; **44**: 357–63.
- 130 Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. *Antimicrob Agents Chemother* 2001; **45**: 2460–67.
- 131 Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant *Staphylococcus aureus* treated with glycopeptides. *Crit Care Med* 2005; **33**: 1983–87.
- 132 Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. *Br J Clin Pharmacol* 2012; **73**: 27–36.
- 133 Wong G, Briscoe S, Adnan S, et al. Protein binding of β -lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? *Antimicrob Agents Chemother* 2013; **57**: 6165–70.
- 134 Gauthier T, Lacarelle B, Marre F, Villard PH, Catalin J, Durand A. Predictive performance of two software packages (USC*PACK PC and Abbott PKS system) for the individualization of amikacin dosage in intensive care unit patients. *Int J Biomed Comput* 1994; **36**: 131–34.
- 135 Pea F, Brollo L, Viale P, Pavan F, Furlanut M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. *J Antimicrob Chemother* 2003; **51**: 971–75.
- 136 Delattre IK, Musuamba FT, Verbeeck RK, et al. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. *Clin Biochem* 2010; **43**: 589–98.
- 137 Pea F, Furlanut M, Cojutti P, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. *Antimicrob Agents Chemother* 2010; **54**: 4605–10.
- 138 Finnell DL, Davis GA, Cropp CD, Ensom MH. Validation of the Hartford nomogram in trauma surgery patients. *Ann Pharmacother* 1998; **32**: 417–21.
- 139 Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. *Antimicrob Agents Chemother* 2009; **53**: 1863–67.
- 140 Pea F, Viale P, Cojutti P, Furlanut M. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. *Antimicrob Agents Chemother* 2012; **56**: 6343–48.
- 141 Mouton JW, Vinks AA. Is continuous infusion of beta-lactam antibiotics worthwhile?—efficacy and pharmacokinetic considerations. *J Antimicrob Chemother* 1996; **38**: 5–15.
- 142 Muller AE, Schmitt-Hoffmann AH, Punt N, Mouton JW. Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study. *Antimicrob Agents Chemother* 2013; **57**: 2047–53.
- 143 Tam VH, Kabbara S, Yeh RF, Leary RH. Impact of sample size on the performance of multiple-model pharmacokinetic simulations. *Antimicrob Agents Chemother* 2006; **50**: 3950–52.
- 144 Roberts JA, Kirkpatrick CM, Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. *J Antimicrob Chemother* 2011; **66**: 227–31.
- 145 Bayard DS, Milman MH, Schumitzky A. Design of dosage regimens: a multiple model stochastic control approach. *Int J Biomed Comput* 1994; **36**: 103–15.
- 146 Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. *Clin Pharmacokinet* 2013; **52**: 9–22.